Search

Your search keyword '"Ferris, Robert L."' showing total 584 results
Start Over Author "Ferris, Robert L." Search Limiters Peer Reviewed
584 results on '"Ferris, Robert L."'

4. Single cell transcriptomic analysis of HPV16-infected epithelium identifies a keratinocyte subpopulation implicated in cancer

Author

Bedard, Mary C., Chihanga, Tafadzwa, Carlile, Adrean, Jackson, Robert, Brusadelli, Marion G., Lee, Denis, VonHandorf, Andrew, Rochman, Mark, Dexheimer, Phillip J., Chalmers, Jeffrey, Nuovo, Gerard, Lehn, Maria, Williams, David E. J., Kulkarni, Aditi, Carey, Molly, Jackson, Amanda, Billingsley, Caroline, Tang, Alice, Zender, Chad, Patil, Yash, Wise-Draper, Trisha M., Herzog, Thomas J., Ferris, Robert L., Kendler, Ady, Aronow, Bruce J., Kofron, Matthew, Rothenberg, Marc E., Weirauch, Matthew T., Van Doorslaer, Koenraad, Wikenheiser-Brokamp, Kathryn A., Lambert, Paul F., Adam, Mike, Steven Potter, S., and Wells, Susanne I.

Published
2023
Full Text
View/download PDF

5. Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial

Author

Kann, Benjamin H, Likitlersuang, Jirapat, Bontempi, Dennis, Ye, Zezhong, Aneja, Sanjay, Bakst, Richard, Kelly, Hillary R, Juliano, Amy F, Payabvash, Sam, Guenette, Jeffrey P, Uppaluri, Ravindra, Margalit, Danielle N, Schoenfeld, Jonathan D, Tishler, Roy B, Haddad, Robert, Aerts, Hugo J W L, Garcia, Joaquin J, Flamand, Yael, Subramaniam, Rathan M, Burtness, Barbara A, and Ferris, Robert L

Published
2023
Full Text
View/download PDF

7. Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504

Author

Gillison, Maura L., Ferris, Robert L., Harris, Jonathan, Colevas, A. Dimitrios, Mell, Loren K., Kong, Christina, Jordan, Richard C., Moore, Kevin L., Truong, Minh-Tam, Kirsch, Claudia, Chakravarti, Arnab, Blakaj, Dukagjin M., Clump, David A., Ohr, James P., Deeken, John F., Gensheimer, Michael F., Saba, Nabil F., Dorth, Jennifer A., Rosenthal, David I., Leidner, Rom S., Kimple, Randall J., Machtay, Mitchell, Curran, Walter J., Jr, Torres-Saavedra, Pedro, and Le, Quynh Thu

Published
2023
Full Text
View/download PDF

10. EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment

Author

Bhatia, Shilpa, Nguyen, Diemmy, Darragh, Laurel B., Van Court, Benjamin, Sharma, Jaspreet, Knitz, Michael W., Piper, Miles, Bukkapatnam, Sanjana, Gadwa, Jacob, Bickett, Thomas E., Bhuvane, Shiv, Corbo, Sophia, Wu, Brian, Lee, Yichien, Fujita, Mayumi, Joshi, Molishree, Heasley, Lynn E., Ferris, Robert L., Rodriguez, Olga, Albanese, Christopher, Kapoor, Mohit, Pasquale, Elena B., and Karam, Sana D.

Published
2022
Full Text
View/download PDF

15. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Author

Lee, Nancy Y, Ferris, Robert L, Psyrri, Amanda, Haddad, Robert I, Tahara, Makoto, Bourhis, Jean, Harrington, Kevin, Chang, Peter Mu-Hsin, Lin, Jin-Ching, Razaq, Mohammad Abdul, Teixeira, Maria Margarida, Lövey, József, Chamois, Jerome, Rueda, Antonio, Hu, Chaosu, Dunn, Lara A, Dvorkin, Mikhail Vladimirovich, De Beukelaer, Steven, Pavlov, Dmitri, Thurm, Holger, and Cohen, Ezra

Published
2021
Full Text
View/download PDF

16. Association of Patient and Tumor Characteristics With Outcomes in Young Head and Neck Squamous Cell Carcinoma Patients.

Author

Hsieh, Ronan W., Gooding, William E., Nilsen, Marci, Kubik, Mark, Kelly, Zahra, Sridharan, Shaum, Skinner, Heath, Iheagwara, Uzoma, Zevallos, Jose P., Duvvuri, Umamaheswar, Kim, Seungwon, Ferris, Robert L., and Zandberg, Dan P.

Abstract

Introduction: We retrospectively studied young patients with head and neck squamous cell carcinoma (HNSCC) to identify factors associated with disease‐specific survival (DSS). Methods: Patient and tumor characteristics of patients aged ≤45 who received treatments for non‐metastatic HNSCC were collected to identify factors associated with DSS. Proportional hazards regression was applied separately for surgical and non‐surgical patients. Results: 230 patients were included. Surgical and non‐surgical patients had similar DSS. Higher pathologic stages, positive margins, perineural invasion (PNI), extranodal extension and negative HPV status were associated with worse DSS for surgical patients and negative HPV status for non‐surgical patients. In the multivariate analysis, pathologic stages, positive margins, and PNI were associated with worse DSS in surgical patients. Conclusion: Pathologic stages, positive margins, and PNI are independently associated with worse DSS in young surgical HNSCC patients. PNI is a uniquely strong prognostic factor for young patients. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

18. Over 132 Years Ago, the Inaugural Immunotherapy Treated Its First Head and Neck Cancer Patient.

Author

Martin, Joey, Hans, Stéphane, Ferris, Robert L., and Baudouin, Robin

Abstract

Immunotherapy in oncology has a more extensive history than is commonly perceived. Rooted in the observations and experiences of multiple physicians in the late 19th century, immunological interventions are currently integral to the oncological therapeutic repertoire. This article seeks to delineate the evolution of cancer immunotherapy, tracing its inception in 1891 with the pioneering work of an American surgeon, William B. Coley, who achieved the first documented cure of a cancer case involving a malignant head and neck tumor. The narrative extends to encompass successive historical breakthroughs and prospective developments in this dynamic field. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311

Author

Ferris, Robert L., Flamand, Yael, Holsinger, F. Christopher, Weinstein, Gregory S., Quon, Harry, Mehra, Ranee, Garcia, Joaquin J., Hinni, Michael L., Gross, Neil D., Sturgis, Erich M., Duvvuri, Umamaheswar, Méndez, Eduardo, Ridge, John A., Magnuson, J. Scott, Higgins, Kerry A., Patel, Mihir R., Smith, Russel B., Karakla, Daniel W., Kupferman, Michael E., Malone, James P., Judson, Benjamin L., Richmon, Jeremy, Boyle, Jay O., Bayon, Rodrigo, O'Malley, Bert W., Jr, Ozer, Enver, Thomas, Giovana R., Koch, Wayne M., Bell, R. Bryan, Saba, Nabil F., Li, Shuli, Sigurdson, Elin R., and Burtness, Barbara

Published
2020
Full Text
View/download PDF

20. Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI

Author

Kreimer, Aimée R., Chaturvedi, Anil K., Alemany, Laia, Anantharaman, Devasena, Bray, Freddie, Carrington, Mary, Doorbar, John, D'Souza, Gypsyamber, Fakhry, Carole, Ferris, Robert L., Gillison, Maura, Neil Hayes, D., Hildesheim, Allan, Huang, Shao Hui, Kowalski, Luiz P., Lang Kuhs, Krystle A., Lewis, James, Jr, Lowy, Douglas R., Mehanna, Hisham, Ness, Andy, Pawlita, Michael, Pinheiro, Maisa, Schiller, John, Shiels, Meredith S., Tota, Joseph, Mirabello, Lisa, Warnakulasuriya, Saman, Waterboer, Tim, Westra, William, Chanock, Stephen, and Brennan, Paul

Published
2020
Full Text
View/download PDF

23. HPV16 drives cancer immune escape via NLRXI-mediated degradation of STING

Author

Luo, Xiaobo, Donnelly, Christopher R., Gong, Wang, Heath, Blake R., Hao, Yuning, Donnelly, Lorenza A., Moghbeli, Toktam, Tan, Yee Sun, Lin, Xin, Bellile, Emily, Kansy, Benjamin A., Carey, Thomas E., Brenner, J. Chad, Cheng, Lei, Polverini, Peter J., Morgan, Meredith A., Wen, Haitao, Prince, Mark E., Ferris, Robert L., Xie, Yuying, Young, Simon, Wolf, Gregory T., Chen, Qianming, and Lei, Yu.L.

Subjects
Thermo Fisher Scientific Inc. -- Negotiation, mediation and arbitration, Cervical cancer, Biological response modifiers, Papillomavirus infections, Nucleic acids, Coevolution, Squamous cell carcinoma, Pembrolizumab, Interferon, Scientific equipment industry -- Negotiation, mediation and arbitration, T cells, Machine learning, Criminal investigation, Papillomavirus, Carcinoma, Cancer, Tumors, DNA, Health care industry, University of Michigan. School of Dentistry -- Negotiation, mediation and arbitration
Abstract

The incidence of human papillomavirus-positive (HPV*) head and neck squamous cell carcinoma (HNSCC) has surpassed that of cervical cancer and is projected to increase rapidly until 2060. The coevolution of HPV with transforming epithelial cells leads to the shutdown of host immune detection. Targeting proximal viral nucleic acid-sensing machinery is an evolutionarily conserved strategy among viruses to enable immune evasion. However, E7 from the dominant HPV subtype 16 in HNSCC shares low homology with HPV18 E7, which was shown to inhibit the STING DNA-sensing pathway. The mechanisms by which HPV16 suppresses STING remain unknown. Recently, we characterized the role of the STING/ type I interferon (IFN-I) pathway in maintaining immunogenicity of HNSCC in mouse models. Here we extended those findings into the clinical domain using tissue microarrays and machine learning-enhanced profiling of STING signatures with immune subsets. We additionally showed that HPV16 E7 uses mechanisms distinct from those used by HPV18 E7 to antagonize the STING pathway. We identified NLRX1 as a critical intermediary partner to facilitate HPV16 E7-potentiated STING turnover. The depletion of NLRX1 resulted in significantly improved IFN-I-dependent T cell infiltration profiles and tumor control. Overall, we discovered a unique HPV16 viral strategy to thwart host innate immune detection that can be further exploited to restore cancer immunogenicity., Introduction The coevolution of oncogenic viruses with transforming epithelial cells encourages pathogens to develop unique mechanisms that enable immune evasion. The type I interferon (IFN-I) system is an ancient and [...]

Published
2020
Full Text
View/download PDF

26. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function

Author

Kumar, Manish, Molkentine, David, Molkentine, Jessica, Bridges, Kathleen, Xie, Tongxin, Yang, Liangpeng, Hefner, Andrew, Gao, Meng, Bahri, Reshub, Dhawan, Annika, Frederick, Mitchell J., Seth, Sahil, Abdelhakiem, Mohamed, Beadle, Beth M., Johnson, Faye, Wang, Jing, Shen, Li, Heffernan, Timothy, Sheth, Aakash, Ferris, Robert L., Myers, Jeffrey N., Pickering, Curtis R., and Skinner, Heath D.

Published
2021
Full Text
View/download PDF

27. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing

Author

Kürten, Cornelius H. L., Kulkarni, Aditi, Cillo, Anthony R., Santos, Patricia M., Roble, Anna K., Onkar, Sayali, Reeder, Carly, Lang, Stephan, Chen, Xueer, Duvvuri, Umamaheswar, Kim, Seungwon, Liu, Angen, Tabib, Tracy, Lafyatis, Robert, Feng, Jian, Gao, Shou-Jiang, Bruno, Tullia C., Vignali, Dario A. A., Lu, Xinghua, Bao, Riyue, Vujanovic, Lazar, and Ferris, Robert L.

Published
2021
Full Text
View/download PDF

28. B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma

Author

Ruffin, Ayana T., Cillo, Anthony R., Tabib, Tracy, Liu, Angen, Onkar, Sayali, Kunning, Sheryl R., Lampenfeld, Caleb, Atiya, Huda I., Abecassis, Irina, Kürten, Cornelius H. L., Qi, Zengbiao, Soose, Ryan, Duvvuri, Umamaheswar, Kim, Seungwon, Oesterrich, Steffi, Lafyatis, Robert, Coffman, Lan G., Ferris, Robert L., Vignali, Dario A. A., and Bruno, Tullia C.

Published
2021
Full Text
View/download PDF

33. International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancers.

Author

Liem, Xavier, de Baère, Thierry, Vivar, Omar I., Seiwert, Tanguy Y., Shen, Colette, Pápai, Zsuzsanna, Moreno, Victor, Takácsi‐Nagy, Zoltán, Helfferich, Frigyes, Thariat, Juliette, Gooi, Zhen, Yom, Sue S., Bossi, Paolo, Ferris, Robert L., Hackman, Trevor G., Le Tourneau, Christophe, Rodriguez, Joseph, and Hoffmann, Caroline

Subjects
HEAD & neck cancer, INJECTIONS, NANOPARTICLES, DELPHI method, SQUAMOUS cell carcinoma
Abstract

Background: An international multidisciplinary panel of experts aimed to provide consensus guidelines describing the optimal intratumoral and intranodal injection of NBTXR3 hafnium oxide nanoparticles in head and neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, and cervical lymph nodes and to review data concerning safety, feasibility, and procedural aspects of administration. Methods: The Delphi method was used to determine consensus. A 4‐member steering committee and a 10‐member monitoring committee wrote and revised the guidelines, divided into eight sections. An independent 3‐member reading committee reviewed the recommendations. Results: After two rounds of voting, strong consensus was obtained on all recommendations. Intratumoral and intranodal injection was deemed feasible. NBTXR3 volume calculation, choice of patients, preparation and injection procedure, potential side effects, post injection, and post treatment follow‐up were described in detail. Conclusions: Best practices for the injection of NBTXR3 were defined, thus enabling international standardization of intratumoral nanoparticle injection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Th2 Cells Are Associated with Tumor Recurrence Following Radiation.

Author

Abdelhakiem, Mohamed K., Bao, Riyue, Pifer, Phillip M., Molkentine, David, Molkentine, Jessica, Hefner, Andrew, Beadle, Beth, Heymach, John V., Luke, Jason J., Ferris, Robert L., Pickering, Curtis R., Wang, Jing H., Patel, Ravi B., and Skinner, Heath D.

Subjects
CANCER relapse, T cells, RESEARCH funding, RADIOTHERAPY, HEAD & neck cancer, IMMUNE system, TUMOR markers, LONGITUDINAL method, GENE expression, DNA damage, GENETIC mutation, DISEASE risk factors
Abstract

Simple Summary: Locoregional recurrence following the definitive treatment of head and neck cancers often leads to patient demise. Radiation is frequently used in the definitive treatment of these cancers. Resistance to radiation leads to increased locoregional recurrence, particularly in patients with human papillomavirus-negative head and neck squamous cell carcinomas. In this study, we show that tumor Th2 immune infiltrate is associated with increased locoregional recurrence in patients with human papillomavirus-negative head and neck squamous cell carcinoma. These findings can be used to develop novel immunotherapeutic approaches to improve the response to radiation and thus decrease locoregional recurrence and improve outcomes in patients with human papillomavirus-negative head and neck squamous cell carcinomas. The curative treatment of multiple solid tumors, including head and neck squamous cell carcinoma (HNSCC), utilizes radiation. The outcomes for HPV/p16-negative HNSCC are significantly worse than HPV/p16-positive tumors, with increased radiation resistance leading to worse locoregional recurrence (LRR) and ultimately death. This study analyzed the relationship between immune function and outcomes following radiation in HPV/p16-negative tumors to identify mechanisms of radiation resistance and prognostic immune biomarkers. A discovery cohort of 94 patients with HNSCC treated uniformly with surgery and adjuvant radiation and a validation cohort of 97 similarly treated patients were utilized. Tumor immune infiltrates were derived from RNAseq gene expression. The immune cell types significantly associated with outcomes in the discovery cohort were examined in the independent validation cohort. A positive association between high Th2 infiltration and LRR was identified in the discovery cohort and validated in the validation cohort. Tumor mutations in CREBBP/EP300 and CASP8 were significantly associated with Th2 infiltration. A pathway analysis of genes correlated with Th2 cells revealed the potential repression of the antitumor immune response and the activation of BRCA1-associated DNA damage repair in multiple cohorts. The Th2 infiltrates were enriched in the HPV/p16-negative HNSCC tumors and associated with LRR and mutations in CASP8, CREBBP/EP300, and pathways previously shown to impact the response to radiation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design.

Author

Ferris, Robert L, Mehanna, Hisham, Schoenfeld, Jonathan D, Tahara, Makoto, Yom, Sue S, Haddad, Robert, König, André, Witzler, Pauline, Bajars, Marcis, and Tourneau, Christophe Le

Abstract

There is a significant unmet need and lack of treatment options for patients with resected, high-risk, cisplatin-ineligible locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Xevinapant, a first-in-class, potent, oral, small-molecule IAP inhibitor, is thought to restore cancer cell sensitivity to chemotherapy and radiotherapy in clinical and preclinical studies. We describe the design of XRay Vision (NCT05386550), an international, randomized, double-blind, phase III study. Approximately 700 patients with resected, high-risk, cisplatin-ineligible LA SCCHN will be randomized 1:1 to receive 6 cycles of xevinapant or placebo, in combination with radiotherapy for the first 3 cycles. The primary end point is disease-free survival, and secondary end points include overall survival, health-related quality of life, and safety. Squamous cell carcinoma is the most common form of head and neck cancer (SCCHN) and includes cancers of the lips, mouth, throat, tongue and voice box. It is called 'locally advanced' when the cancer has spread to nearby areas but not to other parts of the body. Few treatment options are available for people with locally advanced SCCHN who have had surgery and are unable to receive a type of chemotherapy called cisplatin. Xevinapant is being developed as a possible new type of cancer treatment. It is a liquid that is taken by mouth or given through a feeding tube. Adding xevinapant to the standard treatment – called radiotherapy – aims to make radiotherapy more effective against the cancer. Researchers have started a large, international, phase III study called XRay Vision to see if adding xevinapant to radiotherapy can help stop the cancer from coming back after surgery and help people live longer. Clinical Trial Registration: NCT05386550 (ClinicalTrials.gov) Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Author

Ferris, Robert L., Blumenschein, George, Jr., Fayette, Jerome, Guigay, Joel, Colevas, A. Dimitrios, Licitra, Lisa, Harrington, Kevin J., Kasper, Stefan, Vokes, Everett E., Even, Caroline, Worden, Francis, Saba, Nabil F., Docampo, Lara Carmen Iglesias, Haddad, Robert, Rordorf, Tamara, Kiyota, Naomi, Tahara, Makoto, Lynch, Mark, Jayaprakash, Vijayvel, Li, Li, and Gillison, Maura L.

Published
2018
Full Text
View/download PDF

43. A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer

Author

Vargo, John A., Ward, Matthew C., Caudell, Jimmy J., Riaz, Nadeem, Dunlap, Neal E., Isrow, Derek, Zakem, Sara J., Dault, Joshua, Awan, Musaddiq J., Higgins, Kristin A., Hassanadeh, Comron, Beitler, Jonathan J., Reddy, Chandana A., Marcrom, Samuel, Boggs, Drexell H., Bonner, James A., Yao, Min, Machtay, Mitchell, Siddiqui, Farzan, Trotti, Andy M., Lee, Nancy Y., Koyfman, Shlomo A., Ferris, Robert L., and Heron, Dwight E.

Published
2018
Full Text
View/download PDF

45. Data Set for the Reporting of Carcinomas of the Major Salivary Glands: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting

Author

Seethala, Raja R., Altemani, Albina, Ferris, Robert L., Fonseca, Isabel, Gnepp, Douglas R., Ha, Patrick, Nagao, Toshitaka, Skalova, Alena, Stenman, Goran, and Thompson, Lester D.R.

Subjects
Practice guidelines (Medicine) -- Analysis, Salivary gland tumors -- Research, Physicians, Cancer, Medical research, Tumors, Health
Abstract

* The International Collaboration on Cancer Reporting is a nonprofit organization whose goal is to develop evidence-based, internationally agreed-upon standardized data sets for each anatomic site, to be used throughout the world. Providing global standardization of pathology tumor classification, staging, and other reporting elements will lead to achieving the objective of improved patient management and enhanced epidemiologic research. Salivary gland carcinomas are relatively uncommon, and as such, meaningful data about the many histologic types are not easily compared. Morphologic overlap between tumor types makes accurate classification challenging, but there are often significant differences in patient outcomes. Therefore, issues related to tumor type, tumor grading, high-grade transformation, extent of invasion, number and size of nerves affected, and types of ancillary studies are discussed in the context of daily application to specimens from these organs. This review focuses on the data set developed for salivary gland carcinomas with discussion of the key core and noncore elements developed for inclusion by an international expert panel of head and neck and oral-maxillofacial pathologists and surgeons. doi: 10.5858/arpa.2018-0422-SA, With the aim of standardizing evidence-based pathology reports for use throughout the world, the International Collaboration on Cancer Reporting (ICCR) since 2011 has developed data sets for various organ systems. [...]

Published
2019
Full Text
View/download PDF

46. THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer

Author

Panebianco, Federica, Kelly, Lindsey M., Liu, Pengyuan, Zhong, Shan, Dacic, Sanja, Wang, Xiaosong, Singhi, Aatur D., Dhir, Rajiv, Chiosea, Simion I., Kuan, Shih-Fan, Bhargava, Rohit, Dabbs, David, Trivedi, Sumita, Gandhi, Manoj, Diaz, Rachel, Wald, Abigail I., Carty, Sally E., Ferris, Robert L., Lee, Adrian V., Nikiforova, Marina N., and Nikiforov, Yuri E.

Published
2017

48. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141

Author

Kiyota, Naomi, Hasegawa, Yasuhisa, Takahashi, Shunji, Yokota, Tomoya, Yen, Chia-Jui, Iwae, Shigemichi, Shimizu, Yasushi, Hong, Ruey-Long, Goto, Masahiro, Kang, Jin-Hyoung, Sum Kenneth Li, Wing, Ferris, Robert L., Gillison, Maura, Namba, Yoshinobu, Monga, Manish, Lynch, Mark, and Tahara, Makoto

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results